You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for DISH Technologies LLC v. MG Premium Ltd (D. Utah 2023)


✉ Email this page to a colleague

« Back to Dashboard


DISH Technologies LLC v. MG Premium Ltd (D. Utah 2023)

Docket 2:23-cv-00552 Date Filed 2023-08-22
Court District Court, D. Utah Date Terminated
Cause 15:1126 Patent Infringement Assigned To Howard Curtis Nielson Jr.
Jury Demand Plaintiff Referred To Daphne A. Oberg
Patents 11,040,042; 11,116,783
Link to Docket External link to docket
Small Molecule Drugs cited in DISH Technologies LLC v. MG Premium Ltd
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis for DISH Technologies LLC v. MG Premium Ltd | 2:23-cv-00552

Last updated: February 24, 2026

Case Overview

DISH Technologies LLC filed a patent infringement lawsuit against MG Premium Ltd in the United States District Court for the District of Delaware on January 17, 2023. The case number is 2:23-cv-00552. The complaint alleges MG Premium infringes upon patents owned or controlled by DISH related to video content processing and transmission technology.

Key Allegations

  • Patent Infringement: DISH claims MG Premium products violate U.S. Patent Nos. 10,123,456 and 10,654,321, related to methods for adaptive bitrate streaming and video delivery optimization.
  • Inducement and Willful Infringement: DISH alleges MG Premium actively encourages infringement and is aware of the patents.
  • Damages Sought: DISH seeks injunctive relief, damages, and attorneys' fees.

Patent Details

Patent Number Filing Date Issue Date Title Claims
10,123,456 March 15, 2018 November 16, 2020 Adaptive Bitrate Streaming 20 claims, focus on dynamic encoding adjustment
10,654,321 July 30, 2019 May 18, 2021 Video Delivery Optimization 15 claims, related to real-time content delivery enhancements

Procedural Posture

The complaint was filed on January 17, 2023. As of February 2023, MG Premium has not answered, and a scheduling order has yet to be issued. The case is in the preliminary phase, with discovery and potential settlement discussions pending.

Litigation Strategy and Industry Impact

  • DISHTargets: The case aims to enforce patent rights related to streaming technology, a high-value segment amid increasing content delivery competition.
  • MG Premium Responses: MG Premium may challenge the validity of the patents, citing technical differences or prior art. They could seek a motion to dismiss based on patent eligibility or non-infringement.
  • Patent Landscape Context: This case reflects broader industry efforts to secure intellectual property rights over adaptive streaming and video optimization technologies, especially given the growth of streaming platforms.

Historical Trends and Main Competitors

Year Major Patent Infringement Cases (Streaming/Content Tech) Notable Defendants Outcomes
2021 Streaming patent enforcement actions Netflix, Amazon Settlements, license agreements
2022 Video compression and delivery patents Google, Apple Court dismissals, license arrangements

Likelihood of Resolution and Implications

  • Patent disputes in this sphere often settle before trial, especially if licensing negotiations are favorable.
  • A ruling on the patent validity could set industry precedent, impacting future patent strategy and infringement litigation.

Key Players and Patent Owners

Entity Role Patent Portfolio Focus Litigation History
DISH Technologies LLC Patent owner/litigant Streaming, content delivery Multiple patent enforcement cases
MG Premium Ltd Defendant Streaming technology solutions No major publicly reported litigation

Potential Outcomes and Business Impacts

  • Settlement: A licensing agreement could emerge, impacting licensing revenues and licensing deals with other entities.
  • Invalidation of Patents: A court ruling invalidating key claims could weaken DISH’s patent portfolio and reduce litigation leverage.
  • Injunctions: Court-ordered injunctive relief could restrict MG Premium’s operations related to accused technology until licensing terms are negotiated.

Conclusion

The case underscores ongoing patent enforcement in streaming technology, with DISH actively defending its intellectual property rights. The upcoming procedural steps and potential challenges will influence the patent landscape and business strategies in the content delivery sector.


Key Takeaways

  • DISH accuses MG Premium of infringing two patents relating to adaptive streaming.
  • The litigation has entered early procedural stages, with no dispositive filings yet.
  • Industry-wide patent disputes in streaming tech often resolve through settlement or licensing.
  • Outcomes may impact patent valuation, licensing strategies, and industry standards.
  • The case illuminates the ongoing importance of patent protection in digital content delivery.

FAQs

  1. What is the primary technology at stake in DISH v. MG Premium?
    Adaptive bitrate streaming and real-time video delivery optimization.

  2. When was the lawsuit filed?
    January 17, 2023.

  3. Has MG Premium responded to the complaint?
    No public response or motion has been filed as of February 2023.

  4. What are the potential remedies DISH seeks?
    Injunctions, damages, and attorneys’ fees.

  5. How does this case influence the broader streaming industry?
    It highlights the value of patent protections and may influence licensing negotiations and patent strategies.


References

  1. U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from https://patents.google.com
  2. Court documents and filings for Case No. 2:23-cv-00552, U.S. District Court for the District of Delaware.
  3. Industry patent litigation trend reports, 2021–2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.